---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-002718"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:12:34.964656+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nektar reports $329M cash; runway into mid-2026

## Summary
- Preliminary cash and cash equivalents of $329 million as of December 31, 2023.
- Cash runway expected to fund operations into at least mid-2026.
- Management announced at J.P. Morgan Healthcare Conference on January 10, 2024.

## SEC filing metadata
- accession: 0001213900-24-002718
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024002718/0001213900-24-002718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024002718/ea191340-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-002718
- JSON: https://secwatch.observer/filing/0001213900-24-002718.json
- Plain text: https://secwatch.observer/filing/0001213900-24-002718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.